| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Medical Officer
3 companies
Mansoor Raza Mirza is Director at SERA and has filed Form 4s across 3 companies. Mansoor Raza Mirza's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $223K at current prices.
Historically, Mansoor Raza Mirza's trades have earned a strong insider score of 79/100 across 17 rated trades. Over a 12-month horizon, 93.3% of those trades were profitable, with an average 12-month return of +37.3%.
The biggest single holding is SERA (~$158K) as Director. The SERA filings lean toward selling, a net 2,522 shares.
Mansoor Raza Mirza has 54 Form 4 filings on record from May 2015 to July 2026, across 3 companies: Director at Sera Prognostics (SERA), 2022–2026; Chief Medical Officer at Acrivon Therapeutics (ACRV), 2025–2026; Director at Karyopharm Therapeutics (KPTI), 2015–2025.
The 90 reported transactions were 42 open-market sales, 24 option exercises, 19 option or other derivative awards and 5 stock awards.
Counted by filing, the open-market trades come to no purchases and 35 sales worth about $1.6M.
The largest open-market sale was 20,000 shares of KPTI at an average $16.07 on December 7, 2020, about $321K.
None of the 17 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 292 | $3.05 | $890.60 | -0.5% | -33.4% | - | |
| Nov 5, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 221 | $3.04 | $671.84 | -0.4% | -8.7% | - | |
| Oct 6, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 227 | $3.16 | $717.32 | -0.4% | -6.1% | -37.1% | |
| Sep 5, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 222 | $3.35 | $743.70 | -0.4% | -10.8% | -39.5% | |
| Aug 5, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 225 | $2.50 | $562.50 | -0.4% | +30.6% | -18.4% | |
| Jul 7, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 234 | $2.36 | $552.24 | -0.4% | +34.7% | -16.9% | |
| Jun 6, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 107 | $1.58 | $169.06 | -0.2% | +120.0% | +47.7% | |
| May 8, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 106 | $2.44 | $258.64 | -0.2% | +29.7% | -11.3% | |
| Apr 7, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 107 | $3.35 | $358.45 | -0.2% | -28.6% | -36.3% | |
| Mar 6, 2025 | SERA Sera Prognostics, Inc. | Director | Sell | 99 | $4.16 | $411.84 | -0.2% | -59.0% | -53.5% |